Oncology & Cancer

Long-term cardiomyopathy risk varies by chemo agent

(HealthDay)—Long-term cardiomyopathy risk varies by chemotherapy agent for childhood cancer survivors, with a decreased risk for daunorubicin versus doxorubicin, according to a study recently published in JAMA Oncology.

Oncology & Cancer

Evaluating drug regimens for high-risk prostate cancer

The addition of a chemotherapy drug to adjuvant hormone therapy did not improve survival for patients with high-risk prostate cancer after surgery, according to the findings of a new clinical trial.

Medical research

Risk of leukemia with multiple sclerosis drug higher than thought

The risk of developing leukemia as a side effect of a drug for multiple sclerosis (MS) is higher than previously reported, according to a study to be presented as part of the Late-breaking Science Program at the American ...